Volta Medical

Executive Summary

Volta Medical is a French medtech company leveraging artificial intelligence to improve the treatment of cardiac arrhythmias, specifically atrial fibrillation. Founded in 2016 and headquartered in Marseille, the company has developed the VX1 AI software platform designed to assist electrophysiologists in identifying and targeting arrhythmia substrates during catheter ablation procedures. The platform aims to standardize complex ablation workflows, reduce procedure times, and improve patient outcomes. Volta Medical has raised significant venture capital funding from investors such as Sofinnova Partners and has obtained CE marking for its product in Europe. The company is currently expanding into the U.S. market, with a focus on regulatory approval and clinical adoption. Despite the competitive landscape, Volta Medical's AI-driven approach has the potential to address unmet needs in the treatment of persistent and long-standing persistent atrial fibrillation, which remains challenging for conventional ablation techniques.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for VX1 AI ablation system70% success
• Q3 2026Publication of pivotal clinical trial results demonstrating superiority over standard ablation60% success
• Q2 2027Strategic partnership with a major cardiac device manufacturer for global commercialization50% success